Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A
2(50.0%)
Phase 3
1(25.0%)
Phase 1
1(25.0%)
4Total
N/A(2)
Phase 3(1)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT07075328Phase 1Recruiting

A Phase I/II Study of OJP-001 in Patients With Adult T-cell Leukemia/Lymphoma

Role: collaborator

NCT03189641Not ApplicableCompleted

Clinical Trial of Cilostazol Eluting Stent System (CES-1) in De Novo Coronary Artery Lesions

Role: lead

NCT02918305Phase 3Completed

Renal Denervation on Quality of 24-hr BP Control by Ultrasound In Resistant Hypertension

Role: lead

NCT02964702Not ApplicableCompleted

Thrombectomy Revascularization of Intracranial Vessel OcclusioN by Originating From Japan (TRON1-Japan)

Role: lead

All 4 trials loaded